MEN1 and acute leukemia: A recent phase 1 clinical trial indicated that in children and adults with highly refractory acute leukemia with KMT2A gene rearrangement, menin inhibition with Revumenib monotherapy was associated with promising anti-leukemic activity, leading to deep and sustained remission [32].